Chung Hwa Chemical Industrial Works Ltd. AI Stock Analysis
Chung Hwa Chemical Industrial Works Ltd. (1727) AI Stock Analysis
Chung Hwa Chemical Industrial Works Ltd.
(TWSE:1727)
Chung Hwa Chemical scores poorly, driven primarily by severe fundamental deterioration: margin compression has reduced operating profit to near zero, return on equity has fallen to 0.24%, and a large capital spending program pushed free cash flow to negative NT$458.2 million while debt nearly doubled. Technicals reinforce the caution, with the stock trading well below its short- and medium-term moving averages and negative MACD momentum, though oversold readings hint at potential near-term stabilisation. A P/E above 114 and a negligible dividend yield add valuation risk. The principal buffers are a still-conservative balance sheet with equity funding about 60% of assets and cash generation that continues to exceed reported profits — leaving the investment case dependent on the current investment cycle restoring margins and volumes.
Chung Hwa Chemical Industrial Works Ltd. (1727) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 11.67B
- Dividend Yield
- 0.18%
- Average Volume (3M)
- 8.41M
- Price to Earnings (P/E)
- 121.5
- Beta (1Y)
- 1.06
- Revenue Growth
- 20.16%
- EPS Growth
- 962.24%
- Country
- TW
- Employees
- 298
- Sector
- General
- Sector Strength
- 55
- Industry
- Chemicals
Chung Hwa Chemical Industrial Works Ltd. Business Overview & Revenue Model
Company Description
Chung Hwa Chemical Industrial Works, Ltd., established in Taoyuan City, Taiwan, in 1956, is a global enterprise engaged in the manufacturing and distribution of various chemical products. The company's offerings encompass essential industrial chemica...
Chung Hwa Chemical Industrial Works Ltd. Financial Statement Overview
Summary
Financials are weak across the board. Revenue slipped to about NT$1.97 billion with no real growth over five years, while gross margin compressed to 9.5% from 13.0% and operating profit collapsed to a near break-even NT$1.0 million, leaving a 0.26% net margin. Operating cash flow fell sharply to NT$110.3 million from NT$351.6 million, and heavy capital spending drove free cash flow to negative NT$458.2 million, funded by debt that nearly doubled to NT$979.5 million. The main offsets are a still-conservative capital structure (equity funds about 60% of assets, debt-to-equity 0.47), healthy EBITDA near 12% of sales, and operating cash flow that comfortably exceeds reported profit — but return on equity of just 0.24% leaves almost no margin for error.
Income Statement
27NegativeBalance Sheet
54NeutralCash Flow
33Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.16B | 1.97B | 2.08B | 1.72B | 2.31B | 2.01B |
| Gross Profit | 294.60M | 186.25M | 270.46M | 192.71M | 281.95M | 372.60M |
| EBITDA | 336.97M | 236.31M | 311.65M | 223.59M | 269.27M | 356.95M |
| Net Income | 88.17M | 5.11M | 63.13M | 43.73M | 46.90M | 134.25M |
Balance Sheet | ||||||
| Total Assets | 3.80B | 3.51B | 3.04B | 2.85B | 2.85B | 2.59B |
| Cash, Cash Equivalents and Short-Term Investments | 170.34M | 126.37M | 145.54M | 209.12M | 261.67M | 202.39M |
| Total Debt | 1.24B | 979.50M | 530.39M | 652.22M | 807.07M | 611.60M |
| Total Liabilities | 1.64B | 1.42B | 963.50M | 1.01B | 1.28B | 1.11B |
| Stockholders Equity | 2.16B | 2.09B | 2.07B | 1.84B | 1.57B | 1.47B |
Cash Flow | ||||||
| Free Cash Flow | -488.16M | -458.24M | -86.58M | -57.20M | -137.88M | 126.50M |
| Operating Cash Flow | 127.68M | 110.34M | 351.56M | 235.02M | 338.14M | 333.82M |
| Investing Cash Flow | -625.36M | -580.11M | -449.68M | -314.59M | -474.02M | -122.77M |
| Financing Cash Flow | 562.28M | 450.61M | 34.53M | 28.04M | 191.52M | -64.29M |
Chung Hwa Chemical Industrial Works Ltd. Peers Comparison
Overall Rating
TW:650969Neutral
TW:170865Neutral
TW:476459Neutral
TW:475558Neutral
TW:470745Neutral
TW:172739Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 69Neutral | TWD 9.02B | 12.96 | ― | 3.23% | 2.00% | 57.23% | |
| 65Neutral | TWD 11.22B | 11.02 | ― | 3.52% | 3.55% | 34.35% | |
| 59Neutral | TWD 11.49B | 42.72 | ― | 0.76% | 17.96% | 211.40% | |
| 58Neutral | TWD 12.34B | 27.45 | ― | 3.05% | -11.09% | 37.46% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 45Neutral | TWD 11.15B | 21.39 | ― | 0.92% | -9.16% | 67.21% | |
| 39Underperform | TWD 11.75B | 121.53 | ― | 0.18% | 20.16% | 962.24% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:1727 | Chung Hwa Chemical Industrial Works Ltd. | 84.10 | 47.51 | 129.83% | |
| TW:1708 | Sesoda Corporation | 45.40 | 14.45 | 46.66% | |
| TW:4707 | Pan Asia Chemical Corp. | 27.30 | 17.85 | 188.80% | |
| TW:4755 | San Fu Chemical Co., Ltd. | 121.50 | 17.34 | 16.65% | |
| TW:4764 | Double Bond Chemical Ind., Co., Ltd. | 131.00 | 63.18 | 93.16% | |
| TW:6509 | Taiwan Hopax Chemicals Manufacturing Co. Ltd. | 43.20 | 10.94 | 33.93% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026
